View Annual Report

Total Page:16

File Type:pdf, Size:1020Kb

View Annual Report Perrigo Annual Report 2012 Contents 3 Financial Highlights 12 Business Segment Review 22 Financial Reconciliation 4 Shareholder Letter 14 2012 in Review Insert 125 Years of Perrigo 10 Key Events 20 Shareholder Information Corporate Profile 2 From its beginnings as a packager of generic home remedies in 1887, Allegan, Michigan-based Perrigo Company has grown to become a leading global provider of quality, affordable healthcare products. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, dietary supplements and active pharmaceutical ingredients (API). Perrigo is the world’s largest manufacturer of OTC pharmaceutical products for the store brand market. The Company’s primary markets and locations of logistics operations have evolved over the years to include the United States, Israel, Mexico, the United Kingdom, India, China and Australia. Perrigo Annual Report 2012 Financial Highlights Year Ended Financial Results – June 25, June 30, % Reported (GAAP) (1) 2011 (2) 2 012 (2) Change In millions, except shares Net Sales $ 2,755.0 $ 3,173.2 15 and per share amounts Operating Income $ 490.2 $ 569.2 16 Income from Continuing Operations $ 340.6 $ 393.0 15 Diluted Earnings Per Share from Continuing Operations $ 3.64 $ 4.18 15 Average Diluted Shares Outstanding (000s) 93,529 94,052 Year Ended Financial Results – June 25, June 30, % Adjusted (Non-GAAP) (1) 2011 (3) 2 012 (3) Change 3 In millions, except shares Net Sales $ 2,755.0 $ 3,173.2 15 and per share amounts Operating Income $ 541.3 $ 686.6 27 (unaudited) Income from Continuing Operations $ 375.4 $ 469.4 25 Diluted Earnings Per Share from Continuing Operations $ 4.01 $ 4.99 24 Average Diluted Shares Outstanding (000s) 93,529 94,052 4.99 3,173.2 4.01 2,755.0 686.6 541.3 469.4 375.4 2011 2012 2011 2012 2011 2012 2011 2012 Net Sales Operating Income Income From Diluted Earnings ($ in millions) ($ in millions) Continuing Operations Per Share ($ in millions) (in dollars) (1) All information based on continuing (3) See reconciliation of non-GAAP financial measures on page 22. We have operations. excluded certain items when monitoring and evaluating Perrigo’s ongoing financial results, because we believe this provides important insight into (2) See Item 7 in the Form 10-K report for a Perrigo’s ongoing core business operations on a normalized basis. discussion of results of operations. Perrigo Annual Report 2012 Fellow Shareholders, As I reflect on a successful fiscal year 2012, I can’t help but look back to the very beginnings of the Perrigo Company, 125 years ago. What Luther Perrigo started as a general store and apple drying business near Allegan, Michigan in 1887, has grown to become the $3 billion global healthcare products corporation it is today. More than anything, I am struck by how Perrigo’s long commitment to its core values has guided it throughout its 125-year history, and will continue to do so going forward. A section later in this report reflects on Perrigo’s first 125 years. Fiscal 2012’s results are a testament of how our commitment to a singular mission enables us to deliver value to our shareholders, our customers and consumers. 4 Our past is the foundation of our future. 12 5 years 1,000 products Perrigo remains focused on its mission Perrigo manufactures and packages more than 1,000 products, of providing quality, affordable healthcare including many of the leading over-the-counter, pharmaceutical, for the next 125 years! dietary supplement and nutritional products that are offered in the U.S. market today. 5 million sq. ft. With over 5 million sq. ft. of manufacturing, research and development, and logistics facilities, Perrigo has the necessary economies of scale to be a leader in the global healthcare market. The facilities, if combined, would fill two Empire State Buildings! Perrigo Annual Report 2012 For shareholders, we delivered record sales and earnings, dividend growth, and the market rewarded us with record share prices. For customers, we continued to lead our industry in introducing innovative products and providing superior service in support of their profit goals. And for consumers, we estimate that we delivered $5 billion in healthcare savings in fiscal 2012. These record results were achieved through the dedication and commitment of nearly 9,000 Perrigo team members worldwide. They drove growth in all areas of our core business, brought important new products to market, and helped us identify and complete strategic acquisitions that extended our geographic reach and provided us entry into important new over-the counter (OTC) and prescription (Rx) pharmaceutical categories. 5 Our past is the foundation of our future. Perrigo Annual Report 2012 Five Pillars Drive Our Strategy and Support Our Mission Perrigo’s record performance in fiscal 2012 was the result of our commitment to the key framework of our business strategy: High Quality, Customer Service, Innovation, Cost Management, and People. Ensuring Sustainable High Quality To achieve sustainable quality, Delivering Superior Customer Service We know that our neighbors and we invest heavily in it. We hire At Perrigo, customer service is much families count on the quality of our highly qualified people, continuously more than someone answering the products, just as our retail customers train them, incorporate best-in-class phone when a customer calls, or and value-conscious consumers do. quality control systems, and invest attending to a problem when one We never forget that or lose focus in state-of-the-art equipment. develops. Our customer relationships on the importance of quality in represent true partnerships. In the case For example, nearly 8 percent of our value equation. of our store brand OTC products, the cost of producing a bottle of it’s the customer’s name on the 6 aspirin is attributable to quality package, not ours. And in the case control and maintenance. Perrigo vs. S&P, DJIA, and NASDAQ Price $400 Performance PERRIGO $350 S&P DJIA $300 NASDAQ $250 $200 $150 $100 $50 | | | | | June 08 June 09 June 10 June 11 June 12 Perrigo Annual Report 2012 of our Rx products, it’s the customer’s formulations, and more efficient Perrigo People: Our Strongest Pillar reputation for providing their patients production and packaging solutions. With nearly 9,000 employees with the highest quality available worldwide, it is sometimes easy to Executing Effective Cost Management that’s at stake. Our partnerships lose sight of the critically important Anyone can cut costs, but at what are based on a high level of trust role that each team member price? When you are as committed because our customers place their plays in Perrigo’s overall success. to providing quality, affordable own brands in our hands. Yet, each individual’s dedication and healthcare products as we are, commitment to our core values and Pursuing Industry Leading Innovation you rely on your core values to adherence to our Five Pillars enables To us, “innovation” means being first determine the criteria you use us to consistently deliver quality, to bring new healthcare products in analyzing costs. Then, you make affordable healthcare products and to market, and continuously looking decisions on how to effectively superior financial results. We invest for new ways to leverage our manage those cost factors in a significant resources in attracting, expertise in mass customization to way that enhances the quality training and keeping top talent in deliver healthcare value. As the and affordability of your products. every functional area, wherever global leader in producing high- That’s why “quality” comes first in we operate worldwide. quality store brand and generic our value equation, and first in pharmaceuticals, we continuously our list of strategic pillars. pursue new, industry-leading 7 Remembering Rafi Lebel 1957 - 2012 Perrigo Israel president Rafi Lebel died unexpectedly on March 11, 2012 during a business trip to the U.S. Rafi joined the business when Perrigo acquired Agis Industries in 2005, and had served as president of Perrigo Israel for the past five years. It was Rafi’s endearing friendship, among other things, that helped us work together to combine two companies from two distinctly different parts of the world and, ultimately, paved the way for our success. Most of all, regardless of the topic or whether we agreed or not, Rafi always made sure that we ended each day as friends. And eventually, as friends, we were all able to accomplish much more than simply as colleagues. During his many years at Perrigo, Rafi led amazing achievements, and his numerous contributions made Perrigo a better company. Rafi’s energy, determination, abilities and compassion will be greatly missed. Perrigo Annual Report 2012 Key Events Fiscal year 2012 was an active year in terms of new product launches, which, along with strategic acquisitions, is a key component of our growth strategy and a significant driver behind our results for the year. Paddock Acquisition Epinastine HCl Launch Guaifenesin Extended-Release Early in fiscal 2012, we completed our In November 2011, we were excited Tablets, 600 mg acquisition of Paddock Laboratories, Inc., to launch epinastine HCl ophthalmic In December 2011, we received FDA a privately-held, Minneapolis- solution, 0.05%, a generic version approval for guaifenesin extended- ® based manufacturer of generic Rx of Elestat , after our partner, release tablets, 600 mg, a generic pharmaceuticals, for approximately PharmaForce/Luitpold Pharmaceuticals, version of Mucinex® 600 mg tablets. $540 million in cash. This acquisition received final regulatory approval. Then, in January 2012, we was another important step forward Elestat® is a sterile ophthalmic solution announced that the United States in executing our strategy to expand containing epinastine that is used District Court for the Western District 10 our specialty portfolio of generic R to help prevent itching of the eye x of Michigan granted summary products.
Recommended publications
  • Product & Price# of Barcodes
    Product & Price# of Barcodes <span class="hilite">Cleaning</span> Air Wick Freshmatic Ultra1 Starter Kit (2 gadgets + 2 refills) - $12.99 Air Wick Freshmatic Ultra4 Refill (4 pack/6.17 oz) - $13.99 Air Wick Scented Oils1 (1 warmer + 7 refills) - $11.99 Air Wick Scented Oils1 Refill (8 pack) - $12.99 Air Wick Candles (twin2 pack) - $9.99 Clorox Foaming Bathroom3 Cleaner (3 pack/30 oz) - $8.49 Clorox Toilet Wand (361 ct refill with bonus wand) - $16.49 Clorox Automatic Toilet1 Bowl Cleaner (6 ct/3.5 oz) - $10.79 Clorox Disinfecting Wipes1 (5 pack/78 ct) - $14.99 Clorox Green Works Natural2 Cleaner (twin pack) - $4.99 Clorox Oxi Magic (7.81 lbs) - $9.99 Clorox Clean Up (1802 oz + 32 oz trigger) - $10.49 Clorox Pool & Spa Shock1 Plus, 12 pk./1 lb. $34.99 Clorox Pool & Spa Algaecide and Clarifier, 2 pk./1 gal. $14.99 Clorox Pump 'n Clean (2 pumps + 2 refills/18 oz) - $9.99 Clorox Bleach (2/182 2oz bottles) - $5.99 Damp Rid Moisture 46 Pack Hanging - $9.99 DampRid Buckets (6 pack)1 - $9.99 Fabuloso All Purpose 3Cleaner (169 oz) - $7.99 Febreze Air Effects (32 pack/9.7 oz) - $6.99 Febreze Air Effects Heavy1 Duty Crisp Clean Air Freshener (twin pack/19.4 oz) - $5.99 Febreze Set and Refresh2 (2 ct) - $7.99 Febreze Fabric 2 ct. 541 oz. - $7.99 Febreze Car Vent Clips3 (4 ct) $8.99 Febreze Unstopables2 (3 pack/8.8 oz) 8.99 Formula 409 (180 oz 1+ 32 oz) - $11.99 Glade PlugIns (2 warmers1 + 6 refills) - $11.49 Glade PlugIns (8 pack2 refill) - $12.99 Kaboom (twin pack/403 oz) - $8.79 Liquid Plumbr Foam Pipesnake2 (3 pack/17 oz) - $8.99 Liquid Plumbr ProStrength3 (twin pack/80 oz) - $9.99 Lysol Neutra Air (3 pack/164 oz) - $9.99 Lysol Neutra Air Sanitizing4 Spray, 3 pk./16 oz.
    [Show full text]
  • Rb-Annual-Report-2017.Pdf
    Reckitt Benckiser Group plc(RB) Healthier Annual Report and Financial Statements 2017 Statements Financial and Report Annual Lives, Happier Homes Bringing Our Purpose to Life Reckitt Benckiser Group plc (RB) Annual Report and Financial Statements 2017 RB is inspired by a vision of a world where people are healthier and live better. We continually invest and innovate to find new ways for people to look after themselves, their families and their homes. We believe passionately in doing things the right way and have a culture that pushes us to outperform, every day. Contents Strategic Report Transformation of RB page 01 Highlights 02 Our business model 04 Chairman’s Statement 6 06 Chief Executive’s Statement 10 Strategic objectives, targets and key performance indicators 14 betterbusiness in action 20 bettersociety in action 22 betterenvironment in action 24 Operating review 30 Megatrends 32 Health 34 Hygiene Home Strategy page 36 Financial review 42 Our framework for risk management betterbusiness 10 Governance 52 Board of Directors 56 Executive Committee bettersociety 58 Corporate Governance– Chairman’s Statement 61 Corporate Governance Statement betterenvironment 69 Nomination Committee Report 71 Audit Committee Report 76 Corporate Responsibility, Sustainability, Ethics and Compliance Committee Report Mead Johnson Nutrition Sale of 78 Directors’ Remuneration Report integration RB Food 82 Remuneration Policy at a glance 83 Implementation of specific commitments made to page Shareholders for 2017 84 Annual Report on Remuneration 95 Report
    [Show full text]
  • +1-516-204-7793 Product Catalog
    MVP TRADING CO., INC. PRODUCT CATALOG - 2015 TEL: +1-516-204-7793 UNITS CATEGORY UNIT UPC DESCRIPTION PER CASE ACNE AIDS 724742007614 ALBA ACNE FACE/BDY WASH 8 OZ 6 ACNE AIDS 724742007638 ALBA DEEP CLEAN ACNE WASH 6 OZ 6 ACNE AIDS 724742007607 ALBA PORE ACNE WASH 6 OZ 6 ACNE AIDS 654749453872 AVALON BALANCING TONER 8.5 OZ 6 ACNE AIDS 724742003623 AVALON HONEY MANGO GEL 12OZ 12 ACNE AIDS 839977008012 CLEARASIL .65OZ ADULT CARE CRM 24 ACNE AIDS 839977005356 CLEARASIL 6.5OZ HYDRA O/F SENS 12 ACNE AIDS 39977005343 CLEARASIL 6.5OZ HYDRA O/F WASH 12 ACNE AIDS 839977009200 CLEARASIL ULT D/P CLN PADS 90'S 6 ACNE AIDS 839977005325 CLEARASIL ULT RAP ACT GEL 6.78Z 6 ACNE AIDS 839977009095 CLEARASIL ULT VANISH CREAM 1 OZ 24 ACNE AIDS 839977005073 CLEARASIL ULT WSH/MASK 6.78 OZ 6 ACNE AIDS 839977009224 CLEARASIL ULTRA FACE WASH 6.78Z 12 ACNE AIDS 381370035664 CLN & CLR CLEAR TCH SHEETS 50CT 24 ACNE AIDS 381370033424 CLN & CLR DLY PORE CLNSER 5.5OZ 24 ACNE AIDS 381371020805 CLN & CLR MORN BRST FACE CLNS 8 24 ACNE AIDS 381371020829 CLN & CLR MORN BRST FC SCRB 5Z 24 ACNE AIDS 381371157648 CLN & CLR NT RLX DP CLN FACE 8Z 24 ACNE AIDS 381370033875 CLN & CLR SENS FACIAL CLNR 8 OZ 24 ACNE AIDS 381370039914 CLN & CLR.75OZ ADV ACNE TRTMNT 24 ACNE AIDS 70501116906 NEUT #1169 CLR-PORE OIL CNT 8OZ 24 ACNE AIDS 70501153666 NEUT #15366 OIL-FR ACNE WSH 6OZ 12 ACNE AIDS 70501020036 NEUT #2003 4.2Z RAZ/DEF D/SCRUB 12 ACNE AIDS 70501020135 NEUT #2013 MEN MD LOTION SPF20 12 ACNE AIDS 70501023549 NEUT #2354 ADV ACNE THERAPY SYS 12 ACNE AIDS 70501027004 NEUT #270 ALCOHOL-FR
    [Show full text]
  • Michael Rubin, Et Al. V. Mead Johnson Nutrition Company, Et Al. 17-CV
    Case 1:17-cv-00325-LPS Document 1 Filed 03/27/17 Page 1 of 33 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE MICHAEL RUBIN, On Behalf of Himself ) and All Others Similarly Situated, ) ) Plaintiff, ) Case No. ____________ ) ) JURY TRIAL DEMANDED v. ) CLASS ACTION ) MEAD JOHNSON NUTRITION ) COMPANY, PETER KASPER JAKOBSEN, ) JAMES M. CORNELIUS, STEVEN M. ) ALTSCHULER, HOWARD B. BERNICK, ) KIMBERLY A. CASIANO, ANNA C. ) CATALANO, CELESTE A. CLARK, ) STEPHEN W. GOLSBY, MICHAEL ) GROBSTEIN, PETER G. RATCLIFFE, ) MICHAEL A. SHERMAN, ELLIOTT ) SIGAL, and ROBERT S. SINGER, ) Defendants. ) COMPLAINT FOR VIOLATION OF THE FEDERAL SECURITIES LAWS Plaintiff Michael Rubin (“Plaintiff”), by and through his undersigned counsel, for his complaint against defendants, alleges upon personal knowledge with respect to himself, and upon information and belief based upon, inter alia, the investigation of counsel as to all other allegations herein, as follows: NATURE OF THE ACTION 1. This is a class action brought on behalf of the public stockholders of Mead Johnson Nutrition Company (“Mead Johnson” or the “Company”) against Mead Johnson and its Board of Directors (the “Board” or the “Individual Defendants”) for their violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”), 15.U.S.C. §§ Case 1:17-cv-00325-LPS Document 1 Filed 03/27/17 Page 2 of 33 PageID #: 2 78n(a), 78t(a), and U.S. Securities and Exchange Commission (“SEC”) Rule 14a-9, 17 C.F.R. 240.14a-9, and to enjoin the vote on a proposed transaction, pursuant to which Mead Johnson will be acquired by Reckitt Benckiser Group plc (“Reckitt Benckiser”), through its wholly- owned subsidiary Marigold Merger Sub, Inc.
    [Show full text]
  • General Catalog.Pdf
    ICM ID UPC Item Description Manufacturer MFG ID Min Retail 00105071 024291115229 Bamboo Stir Fry Set 3 Pc Navajo Manufacturing Co, Inc. 25805 2 $ 4.99 00105230 046354315407 Magnetic Numbers & Letters Ja-Ru, Inc. 1405 2 $ 2.99 00105256 046354732600 Glider Air Force Foam Jet 1/cd Ja-Ru, Inc. 2311 2 $ 2.99 00105277 047878650005 Cooler Can Holder U.S. Poly Enterprise, Inc. S650A-BK200 2 $ 2.99 00105283 714415016807 Neon Shot Glasses 12ct Evriholder Products, LLC. SGLSICM0672 2 $ 2.99 00106116 039052810138 TS Luggage Smart Tags 2ct Conair Corporation TS92NLT 3 $ 4.99 00106119 039052008993 TS Adapter Plug 4pc Insulated Plugs Conair Corporation M500ENR 1 $ 17.99 00106133 039052813603 TS Deluxe PVC Luggage Tags 2ct Conair Corporation TS02VB 3 $ 4.99 00183145 085455201578 Opener Beer Bottle/Can Tapper Chef Craft Corporation 20157-TKT 2 $ 2.99 00183699 085455210808 Cocktail Sword Spears Asst 30ct Chef Craft Corporation 21080-TKT 2 $ 1.99 00183913 815290025011 Sink Scents Assorted Liv-It! LLC 501 2 $ 2.99 00184879 871290005941 Foot File - Perfect Pair 1/cd Donnamax, Inc. 134148 2 $ 2.99 00185272 616513704351 Eye Care Essentials 4pc Kit Cala - Shin's Trading Co. 70-435B 2 $ 4.99 00185579 769898062278 Blending Wedge - Flower Shaped 6 ct Swissco LLC 6227 2 $ 4.99 00186171 769898070198 Pumice Sponge Swissco LLC 7019 2 $ 4.99 00186775 687969001394 Comb - Soft Touch Shower Comb Swissco LLC 50383 2 $ 4.99 00186858 085455205682 Opener Jar and Cap Rubber 2pk Chef Craft Corporation 20568-TKT 2 $ 1.99 00187062 705654017045 Doggie Clean Up Bags 20pk Pet King Inc PK1704 2 $ 1.69 00187070 763615802512 Combo Cutlery Clear Plastic 48ct King Zak, Inc.
    [Show full text]
  • Medication Guide for a Safe Recovery
    Medication Guide For A Safe Recovery A guide to maintaining sobriety while receiving treatment for other health problems. Revision 1.0 -April 2008 Table of Contents Introduction..................................................................................2 How to Use this Guide..................................................................3 Class A Drugs (Absolutely Avoid)................................................4 Class B Drugs................................................................................8 (With Addiction Medicine Specialist/Doctor Approval Only) Class C Drugs (Generally Safe to Take).....................................12 Alcohol-Free Products..................................................................16 Incidental Exposure Index...........................................................22 www.talbottcampus.com Introduction From the Talbott Recovery Campus Welcome to the Talbott Recovery Campus guide for a safe and sustained recovery. This document was developed through a collaborative effort between some of the best minds in addiction care today and will help you make wise decisions, ensuring that medications you may be prescribed and incidental exposure to alcohol do not threaten your hard won recovery. This guide is divided into three sections and is based on the drug classification system developed nearly 20 years ago by Dr. Paul Earley and recently expanded on by Bruce Merkin, M.D., Renee Enstrom, Nicholas Link and the staff at Glenbeigh hospital. Part one provides a way of categorizing medications
    [Show full text]
  • Icontact Newsletter
    eckitt Benckiser (formerly Reckitt & C sioners of the R olman) Pensio i for pen n Fund No. 69, September 2017 IN THIS ISSUE ROUTINE INCREASE LETTER When Hull’s Weeping Window poppy display moved on, Derby put its best foot forward with a pavement trail leading to a IS ALSO A REASSURANCE display reaching new heights The April letter, tailored to the individual and sent to RBPA at the Old Silk Mill (see P3&9). members advising them of the annual increase in their pension, may be routine but, like the annual update newsletter, is a welcome reassurance in these uncertain economic times. Also on P3 see how Dansom The letter notes: ‘The level of maintain the century-old tradition Lane’s British Legion standard annual increase applied to your Fund of employee welfare, to use the old- came out of retirement for the pension is equal to the year-on-year fashioned but very relevant words. “Poppy for Oppy” display change in the Retail Prices Index In both business and Government, (RPI) at the 31 December prior to the pensions have become a numbers increase. The rate at 31 December game. Deficits thwart takeover 2016 was 2.5%. Therefore, with effect bids; underfunding or retirement from 1 April 2017, your Fund pension age extensions could impoverish will be increased by 2.5%. some pensioners; and it is reported ‘This is in accordance with the that the government relaxation to Fund’s Rules, which provide that the allow pensioners to cash-in early is Trustees must increase pensions in resulting in serious personal debt line with RPI, up to a maximum of 5%.’ problems.
    [Show full text]
  • RB Enhances Consumer Health Position with the Completion of Its Acquisition of the Mead Johnson Nutrition Company
    Contacts: Lynn Kenney – Communications Director, RB North America P: +1 201-953-5348 [email protected] UK +44 (0)1753 217 800 Richard Joyce – SVP, Investor Relations Patty O’Hayer - Director, External Relations and Government Affairs RB enhances consumer health position with the completion of its acquisition of the Mead Johnson Nutrition Company Parsippany, NJ – June 15, 2017 – RB is pleased to announce the completion of the acquisition of the Mead Johnson Nutrition Company (“Mead Johnson”). The transaction takes RB into a global market leadership position in consumer health and hygiene. Mead Johnson brings the addition of two infant and child nutrition Powerbrands Enfa and Nutramigen, and is a natural extension of RB’s existing health portfolio which is trusted around the globe by millions of consumers. Rakesh Kapoor, RB chief executive, said: “The closure of the acquisition marks an inflection point in RB’s evolution to become a leader in consumer health care. By combining the best of RB’s global scale with MJN’s science-based innovation, RB is well positioned to deliver further value for all stakeholders. We continue to execute on our strategy of providing innovative health solutions for healthier lives and happier homes to millions of people around the world.” Mead Johnson will initially operate as a separate division within RB and be led by Aditya Sehgal, who joins RB’s Executive Committee. Aditya’s previous roles included responsibility for RB’s operations in China and North Asia, RB’s global health care division and RB’s North American business. The Mead Johnson division will continue its mission to nourish the world’s children for the best start in life.
    [Show full text]
  • Hygiene Home Our Purpose Is to Make a Difference by Giving People
    Our purpose is to make a difference RB 2.0 reorganising by giving people innovative solutions for long-term growth for healthier lives and happier homes and outperformance Now we are starting a new chapter of sustainable outperformance with the creation of two focused, fully accountable and more agile business units – Health and Two companies, both rich in history Hygiene Home. and expertise, joined forces. Thomas and Reckitt & Sons Mead Johnson Gaviscon Ecolab Lehn & Fink Reckitt and Adams Schiff Nutrition Hypermarcas We are driven by: Isaac Reckitt founded in Hull founded Acquisition Acquisition Acquisition Benckiser Respiratory Acquisition Condom and MJN brings to RB: build the Maud 1840 1905 1970 1987 1994 Merged Therapeutics 2012 Lubricant Front line obsession Foster mill 1999 Acquisition Acquisition Excellence in infant and child nutrition 1819 2008 2016 Category focus and expertise Deep understanding of new parents Ownership & Entrepreneurship Benckiser Reckitt Reckitt & Sons Air Wick Boyle Midway Sold Colman's Boots SSL K-Y Brand Mead Johnson Respected relationships with healthcare founded in launched on merges with J Acquisition Acquisition Food Business Healthcare International Acquisition / Nutrition professionals Ready to disrupt Germany London Stock & J Colman to 1985 1990 1995 Acquisition Acquisition Spin off Indivior Acquisition/ Radical simplification 1823 Exchange become Reckitt 2006 2010 – (RB Pharma) Sold Food Scale and infrastructure in new markets 1888 & Colman 2014 Business 1938 2017 Together we will find new and exciting The future of RB is exciting. The changes ways to promote health and wellbeing, we are making will reignite the potential of from infancy to adulthood around the world our people and our brands and create value for years to come.
    [Show full text]
  • ردﺎﺻﻣﻟا BNF 61-2011 a to Z Drugs Fact-2003
    (A to Z drugs©2011) More than 1300 drugs المصادر: BNF 61-2011 A to Z drugs fact-2003 مﻻحظة : يحتوي هذا الجدول باﻻضافة لﻻدوية الى بعض اللقاحات والفيتامينات والمعادن يستخدم هذا الجدول فقط للتعرف على اسماء اﻻدوية واستخداماتها الطبية....ولمزيد من المعلومات راجع المصادر. Generic name Brand name & class& dosage form indications NO. Abacavir ZIAGEN{ Tablets, Oral solution} Treatment of HIV-1 in combination with other antiretroviral agents. 1. Class: Anti-infective, Antiviral ABATACEPT Orencia{ Intravenous infusion} It is licensed for moderate to severe active rheumatoid arthritis in combination with methotrexate, in patients unresponsive to other disease-modifying 2. Antirheumatic, Cytokine Modulators antirheumatic drugs (including methotrexate or a tumour necrosis factor (TNF) inhibitor); It is also licensed for the treatment of moderate to severe active pol articular juvenile idiopathic arthritis(in combination with methotrexate) in children who have not responded adequately to other disease- modifying antirheumatic drugs (including at least one tumour necrosis factor (TNF) inhibitor). Abciximab REOPRO{ Injection} Adjunct to percutaneous coronary intervention (PCI) to prevent ischemic complications in patients at high risk of abrupt closure of the treated vessel. 3. Intended for use with aspirin and heparin. Class: Antiplatelet aluminium oxide Brasivol{ Paste} acne vulgaris 4. ABRASIVE AGENTS acamprosate calcium CAMPRAL{ Tablet} maintenance of abstinence in alcohol dependence. 5. antialcoholic Acarbose PRECOSE, Glucobay{ Tablet} Patients with NIDDM who have failed dietary therapy. May be used alone or in combination with sulfonylureas. 6. Class: Antidiabetic Acebutolol SECTRAL{ Capsules, Tablets} Management of hypertension and premature ventricular contractions. 7. Class: Beta-adrenergic blocker ACECLOFENAC Preservex {Tablets} pain and inflammation in rheumatoid arthritis, osteoarthritis and ankylosing spondylitis 8.
    [Show full text]
  • Guide to Alcohol-Free Products
    Guide to Alcohol-Free Products & Incidental Exposure Index & Products Containing Alcohol Reprinted By Permission Of The Talbott Recovery Campus HOW TO USE THIS GUIDE FirstLab wishes to thank the Talbott Recovery Campus for granting FirstLab their permission to reprint and distribute this important guide. This document was developed through a collaborative effort between some of the best minds in addiction care today, to help you make wise decisions concerning over-the-counter (OTC) or prescription medications and help you to avoid incidental exposure to alcohol which could threaten your hard won recovery. Please remember that this guide is only intended as a quick reference and never as a substitute for the advice of your own personal physician. It is essential that you inform all of your personal physicians, dentists and other health care providers of your chemical dependency history so that medications can be prescribed safely and appropriately when they are deemed necessary. Never discontinue or make any changes in the doses of medication that you may have been prescribed. Doing so may result in unexpected problems such as withdrawal reactions, which in some cases can be life-threatening. The bottom line is that a recovering addict or alcoholic needs to become a good consumer. Remember that “Recovery Is Its Own Reward.” Being healthy and regaining a happy life is your responsibility! Alcohol-Free Products The following is a selection of alcohol-free products grouped by therapeutic category. The list is not comprehen- sive. Manufacturers change product ingredients and brand names frequently. Always check product labeling for definitive information on specific ingredients.
    [Show full text]
  • Item # Product Description NDC UPC Barcode
    OTC Item # Product Description NDC UPC Barcode 573618 12 HOUR DECG NASAL SPY 15 ML 00904571135 309045711354 516765 12 HOUR DECG NASAL SPY 30 ML 00904571130 309045711309 243832 2ND SKIN BLISTER PAD 5CT 038472504207 409060 2ND SKIN MOIST BURN PAD LARGE 3CT 038472505242 409052 2ND SKIN MOIST BURN PAD MEDIUM 4CT 038472505532 869305 3M TAPE MEDIPORE CLOTH 12X4"X10YD 08333296401 383332964012 821470 3M TAPE MICROPORE PAPER TAN 6X2"X10YD 08333153302 383331533028 351726 4 WAY FAST ACTING NASAL SPRAY 1 OZ 300672086112 558369 4-AMINOPYRIDINE REAGENT CRY 100 GM DS 362991820990 558357 4-AMINOPYRIDINE REAGENT CRY 25 GM DS 362991820983 601732 A.E.R. WITCH HAZEL PAD 40CT 50289325001 786502893257 540179 A+D FIRST AID OINTMENT 1.5OZ 11523720401 041100811639 515734 A+D MEDICATED ZINC OXIDE CREAM 1.5OZ 11523131401 041100811288 515736 A+D MEDICATED ZINC OXIDE CREAM 4OZ 11523131402 041100811325 513689 A+D OINTMENT ORIGINAL 16OZ 041100811349 515748 A+D ORIGINAL OINTMENT 1.5OZ 041100811226 515724 A+D ORIGINAL OINTMENT 4OZ 041100811240 907741 ABREVA CREAM 2GM 00135020001 307660801306 624837 ABREVA CREAM PUMP 2GM 00135020003 307660801559 935106 ABSORBASE OINTMENT 1LB 46287050716 046287507160 935114 ABSORBASE OINTMENT 4OZ 46287050704 346287507048 416891 ABSORBINE JR PLUS PAIN RELIEF LIQ 4OZ 889476412049 511774 ACCU-CHEK AVIVA CONNECT METER 65702057710 365702577107 027033 ACCU-CHEK AVIVA CONTROL SOLUTION 65702010710 365702107106 027019 ACCU-CHEK AVIVA METER 65702010210 365702102101 026068 ACCU-CHEK AVIVA PLUS CARE KIT 65702010110 365702101104 144006 ACCU-CHEK AVIVA
    [Show full text]